[go: up one dir, main page]

UA81226C2 - Peptide-based multimeric targeted contrast agents - Google Patents

Peptide-based multimeric targeted contrast agents Download PDF

Info

Publication number
UA81226C2
UA81226C2 UA2004010709A UA2004010709A UA81226C2 UA 81226 C2 UA81226 C2 UA 81226C2 UA 2004010709 A UA2004010709 A UA 2004010709A UA 2004010709 A UA2004010709 A UA 2004010709A UA 81226 C2 UA81226 C2 UA 81226C2
Authority
UA
Ukraine
Prior art keywords
group
peptide
linker
component
sya
Prior art date
Application number
UA2004010709A
Other languages
English (en)
Ukrainian (uk)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to UAA200601920A priority Critical patent/UA84432C2/ru
Publication of UA81226C2 publication Critical patent/UA81226C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0039—Coumarin dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/122—Macromolecular compounds dimers of complexes or complex-forming compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/124—Macromolecular compounds dendrimers, dendrons, hyperbranched compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
UA2004010709A 2001-07-30 2002-07-30 Peptide-based multimeric targeted contrast agents UA81226C2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
UAA200601920A UA84432C2 (ru) 2001-07-30 2002-07-30 Очищенные пептиды и соединения, которые их содержат

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30872101P 2001-07-30 2001-07-30
PCT/US2002/024261 WO2003011115A2 (fr) 2001-07-30 2002-07-30 Agents de contraste multimères ciblés à base de peptides

Publications (1)

Publication Number Publication Date
UA81226C2 true UA81226C2 (en) 2007-12-25

Family

ID=23195121

Family Applications (2)

Application Number Title Priority Date Filing Date
UA2004010709A UA81226C2 (en) 2001-07-30 2002-07-30 Peptide-based multimeric targeted contrast agents
UAA200601920A UA84432C2 (ru) 2001-07-30 2002-07-30 Очищенные пептиды и соединения, которые их содержат

Family Applications After (1)

Application Number Title Priority Date Filing Date
UAA200601920A UA84432C2 (ru) 2001-07-30 2002-07-30 Очищенные пептиды и соединения, которые их содержат

Country Status (23)

Country Link
US (5) US6991775B2 (fr)
EP (1) EP1420681B1 (fr)
JP (2) JP4298501B2 (fr)
KR (2) KR20080100856A (fr)
CN (1) CN1599577A (fr)
AR (1) AR036196A1 (fr)
AU (1) AU2002318931B2 (fr)
BR (1) BR0211623A (fr)
CA (1) CA2455638C (fr)
CO (1) CO5560528A2 (fr)
EA (1) EA006239B1 (fr)
EC (1) ECSP044996A (fr)
HU (1) HUP0402029A3 (fr)
IL (1) IL160001A0 (fr)
MX (1) MXPA04000967A (fr)
NO (1) NO20040402L (fr)
NZ (1) NZ531338A (fr)
PL (1) PL368807A1 (fr)
TW (2) TWI240632B (fr)
UA (2) UA81226C2 (fr)
WO (1) WO2003011115A2 (fr)
YU (1) YU9404A (fr)
ZA (1) ZA200401606B (fr)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI240632B (en) * 2001-07-30 2005-10-01 Epix Medical Inc Purified peptides for peptide-based multimeric targeted contrast agents
JP2005529839A (ja) * 2001-10-16 2005-10-06 エピックス メディカル， インコーポレイテッド 脈管内病変の検出および処置
AR047692A1 (es) * 2003-07-10 2006-02-08 Epix Medical Inc Imagenes de blancos estacionarios
CA2445420A1 (fr) 2003-07-29 2005-01-29 Invitrogen Corporation Tests de kinase et de phosphatase
US7619059B2 (en) 2003-07-29 2009-11-17 Life Technologies Corporation Bimolecular optical probes
DE102004038134B4 (de) 2004-08-05 2013-07-25 Johann Wolfgang Goethe-Universität Frankfurt am Main Multivalente Chelatoren zum Modifizieren und Organisieren von Zielmolekülen, Verfahren zu ihrer Herstellung sowie ihre Verwendung
JP2008508333A (ja) * 2004-08-05 2008-03-21 ヨハン ウォルフガング ゲーテ−ウニベルジテート フランクフルト アム マイン 標的分子の改変および組織化のための多価キレーター
US20060275217A1 (en) * 2005-05-06 2006-12-07 Caravan Peter D Chemical exchange saturation transfer contrast agents
JP4559922B2 (ja) * 2005-06-21 2010-10-13 株式会社東芝 蛍光性錯体及びそれを用いた照明装置
EP3378496A1 (fr) * 2005-07-13 2018-09-26 Georgia State University Research Foundation, Inc. Agents de contraste et procédés de préparation d'agents de contraste
KR100703593B1 (ko) * 2005-08-08 2007-04-06 경북대학교 산학협력단 Ｄｔｐａ-비스（피콜린아미드）리간드，이를 포함하는가돌리늄 착물 및 이들의 제조 방법
JP5377965B2 (ja) 2005-09-09 2013-12-25 ジョージア ステート ユニバーシティ リサーチ ファウンデーション、インコーポレイテッド 標的化された造影剤および造影剤を標的化するための方法
CA2621763C (fr) * 2005-09-09 2021-04-06 Georgia State University Research Foundation, Inc. Agents de contraste cibles et leurs procedes de ciblage
US8926945B2 (en) 2005-10-07 2015-01-06 Guerbet Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium
US8986650B2 (en) 2005-10-07 2015-03-24 Guerbet Complex folate-NOTA-Ga68
ES2654520T3 (es) * 2005-10-11 2018-02-14 Huntington Medical Research Institutes Agentes de formación de imágenes y métodos de uso de los mismos
EP1955071A4 (fr) 2005-10-28 2009-03-18 Invitrogen Corp Dosages de l'activite kinase et d'ubiquitination
FI20055653L (fi) * 2005-12-08 2007-06-09 Wallac Oy Leimausreagenssi
WO2007073792A1 (fr) * 2005-12-19 2007-07-05 Bayer Schering Pharma Aktiengesellschaft Procede de fabrication de 4,4-diphenylcyclohexanol
US20070293656A1 (en) * 2005-12-29 2007-12-20 Epix Pharmaceuticals, Inc. Collagen binding peptides
EP2054514A4 (fr) 2006-08-04 2009-11-04 Univ Georgia State Res Found Capteurs d'enzyme, procédés de préparation et utilisation de tels capteurs, et procédés de détection de l'activité protéase
US8420327B2 (en) * 2006-12-14 2013-04-16 Georgia State University Research Foundation Analyte sensors, methods for preparing and using such sensors, and methods of detecting analyte activity
US9814672B2 (en) * 2007-03-09 2017-11-14 Susan T. Laing Echogenic vehicle for clinical delivery of plasminogen activator and other fibrin-binding therapeutics to thrombi
FR2914303A1 (fr) 2007-03-28 2008-10-03 Guerbet Sa Composes pour le diagnostic de l'apoptose.
FR2914304B1 (fr) 2007-03-28 2012-11-16 Guerbet Sa Composes pour le diagnostic de maladies liees a l'expression de vcam.
KR101595324B1 (ko) 2008-01-08 2016-02-18 랜티우스 메디컬 이메징, 인크. 영상화 제제로서의 ｎ-알콕시아미드 접합체
US20090208421A1 (en) 2008-02-19 2009-08-20 Dominique Meyer Process for preparing a pharmaceutical formulation of contrast agents
US20090236541A1 (en) * 2008-03-24 2009-09-24 General Electric Company System and Methods for Optical Imaging
EP3498307A1 (fr) * 2008-04-02 2019-06-19 Georgia State University Research Foundation, Inc. Agents de contraste, procédés de préparation d'agents de contraste et procédés d'imagerie
PT2320923E (pt) * 2008-08-07 2015-02-24 Ipsen Pharma Sas Análogos truncados de polipéptido insulinotrópico dependente de glucose
JP2011530509A (ja) * 2008-08-07 2011-12-22 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ Ｎ末端において修飾されたグルコース依存性インスリン分泌刺激ポリペプチド（ｇｉｐ）のアナログ
US9074014B2 (en) 2008-08-07 2015-07-07 Ipsen Pharma S.A.S. Analogues of glucose-dependent insulinotropic polypeptide
CN102170895A (zh) * 2008-08-07 2011-08-31 益普生制药股份有限公司 葡萄糖依赖性促胰岛素多肽类似物
US8889635B2 (en) 2008-09-30 2014-11-18 The Regents Of The University Of Michigan Dendrimer conjugates
WO2010054321A2 (fr) 2008-11-07 2010-05-14 The Regents Of The University Of Michigan Méthodes de traitement de troubles auto-immuns et/ou de troubles inflammatoires
US8864821B2 (en) 2008-11-26 2014-10-21 Visen Medical, Inc. Methods and compositions for identifying subjects at risk of developing stent thrombosis
FR2942227B1 (fr) 2009-02-13 2011-04-15 Guerbet Sa Utilisation de tampons pour la complexation de radionucleides
WO2010121133A2 (fr) 2009-04-17 2010-10-21 The General Hospital Corporation Imagerie multimodale de fibrine
AU2010226479A1 (en) 2009-03-19 2011-09-22 Wyeth Llc Methods for the preparation of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7) -en-2-yl)ethyl]phosphonic acid and precursors thereof
EP2451776B1 (fr) 2009-07-08 2019-09-18 Lantheus Medical Imaging, Inc. Conjugués n-alkoxyamides en tant qu'agents d'imagerie
US20120107248A1 (en) * 2009-07-08 2012-05-03 Mayo Foundation For Medical Education And Research Imaging gastrointestinal volumes and motility
AU2010318637A1 (en) 2009-10-13 2012-05-31 The Regents Of The University Of Michigan Dendrimer compositions and methods of synthesis
US8912323B2 (en) 2009-10-30 2014-12-16 The Regents Of The University Of Michigan Multifunctional small molecules
WO2011152782A1 (fr) * 2010-06-01 2011-12-08 Ge Healthcare Bio-Sciences Ab Nouveau chélateur et son utilisation
FR2968562B1 (fr) 2010-12-14 2013-01-11 Guerbet Sa Composes pour le diagnostic de maladies liees a l'expression de muc5ac
FR2968999B1 (fr) 2010-12-20 2013-01-04 Guerbet Sa Nanoemulsion de chelate pour irm
US9011816B2 (en) * 2011-03-25 2015-04-21 Case Western Reserve University Fibronectin targeting contrast agent
FR2980364B1 (fr) 2011-09-26 2018-08-31 Guerbet Nanoemulsions et leur utilisation comme agents de contraste
WO2013085718A1 (fr) 2011-12-08 2013-06-13 The Regents Of The University Of Michigan Petites molécules multifonctionnelles
FR3001154B1 (fr) 2013-01-23 2015-06-26 Guerbet Sa Magneto-emulsion vectorisee
US9849201B2 (en) * 2013-05-03 2017-12-26 Washington University Homing agents
WO2014210546A1 (fr) 2013-06-27 2014-12-31 University Of Washington Through Its Center For Commercialization Système polymère biocompatible pour le traitement ciblé de troubles thrombotiques et hémostatiques
WO2015017815A1 (fr) 2013-08-01 2015-02-05 Rochester Institute Of Technology Agents modulaires d'imagerie contenant des acides aminés et des peptides
US10471163B2 (en) 2013-09-13 2019-11-12 The General Hospital Corporation Activatable fibrin-binding probes
GB201322456D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
WO2015196208A2 (fr) 2014-06-20 2015-12-23 The General Hospital Corporation Sondes d'imagerie ciblées sur le collagène
EP3294316A4 (fr) * 2015-05-06 2018-10-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. Agents théarapeutiques et agents d'imagerie compagnons ciblant le mc1r
EP3101012A1 (fr) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft Nouveaux composés de chélate de gadolinium pour une utilisation dans l'imagerie par résonance magnétique
WO2017004211A1 (fr) 2015-06-29 2017-01-05 Collagen Medical, LLC Compositions pour l'imagerie du collagène
ES2987778T3 (es) 2015-08-13 2024-11-18 Massachusetts Gen Hospital Conjugados de quelatos a base de manganeso para la imagenología por resonancia magnética molecular
KR102464647B1 (ko) 2016-11-28 2022-11-08 바이엘 파마 악티엔게젤샤프트 자기 공명 영상화에 사용하기 위한 높은 이완도 가돌리늄 킬레이트 화합물
CN106946926A (zh) * 2017-02-27 2017-07-14 西北大学 一种具有多齿氨羧类二聚体螯合剂及其制备方法、应用和分离介质
US11191854B2 (en) 2017-05-05 2021-12-07 Centre For Probe Development And Commercialization Pharmacokinetic enhancements of bifunctional chelates and uses thereof
WO2018204872A2 (fr) 2017-05-05 2018-11-08 Fusion Pharmaceuticals Inc. Anticorps monoclonaux anti-igf-1r et utilisations de ceux-ci
US10093741B1 (en) 2017-05-05 2018-10-09 Fusion Pharmaceuticals Inc. IGF-1R monoclonal antibodies and uses thereof
RU2681318C1 (ru) * 2017-11-24 2019-03-06 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Способ получения иммуносупрессорного пептида Abu-TGIRIS-Abu, меченного ионом Gd3+
WO2020007822A1 (fr) 2018-07-02 2020-01-09 Conservatoire National Des Arts Et Metiers (Cnam) Nanoparticules de bismuth métallique (0), procédé de fabrication et utilisations de celles-ci
WO2020104602A1 (fr) 2018-11-23 2020-05-28 Bayer Aktiengesellschaft Formulation de milieux de contraste et procédé de préparation associé
US20240115744A1 (en) * 2019-10-23 2024-04-11 Peter Caravan Fibrin-binding compounds for imaging and treatment
CN111233714B (zh) * 2020-03-18 2022-04-08 滨海吉尔多肽有限公司 一种maps多肽的制备方法
US20230271983A1 (en) * 2020-07-29 2023-08-31 Universidade De Santiago De Compostela Functionalized isonitriles and products, preparation and uses thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4622420A (en) 1980-03-18 1986-11-11 The Regents Of The University Of California Chelating agents and method
US4957939A (en) * 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4659839A (en) 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
US4897255A (en) 1985-01-14 1990-01-30 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US4880008A (en) 1985-05-08 1989-11-14 The General Hospital Corporation Vivo enhancement of NMR relaxivity
US4678667A (en) 1985-07-02 1987-07-07 501 Regents of the University of California Macrocyclic bifunctional chelating agents
US4831175A (en) * 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5246692A (en) * 1986-09-05 1993-09-21 The United States Of America As Represented By The Secretary Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5099069A (en) 1986-09-05 1992-03-24 Gansow Otto A Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5001230A (en) 1988-02-18 1991-03-19 Schering Corporation T cell activation markers
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB9111199D0 (en) 1991-05-23 1991-07-17 Sandoz Ltd Improvements in or relating to organic compounds
US5364613A (en) * 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
US5641878A (en) 1991-05-15 1997-06-24 Diatron Corporation Porphyrin, azaporphyrin, and related fluorescent dyes free of aggregation and serum binding
US5009069A (en) * 1990-08-24 1991-04-23 Molini Alberto E Method of recovering energy from ocean water
EP0574530A4 (en) * 1991-03-08 1996-04-03 Res Corp Technologies Inc Endothelin antagonists
ES2194846T3 (es) 1992-03-13 2003-12-01 Diatide Inc Peptidos marcados con tecnecio-99m para obtencion de imagenes de inflamacion.
US5637759A (en) 1992-07-30 1997-06-10 The Regents Of The University Of California Metal-ligating amino acid derivatives for MRI and for peptide synthesis
US5705143A (en) * 1994-01-12 1998-01-06 Amersham International Plc Biological targeting agents
US6001809A (en) * 1994-07-11 1999-12-14 Elan Pharmaceuticals, Inc. Inhibitors of leukocyte adhesion
DE69530392D1 (de) 1994-07-11 2003-05-22 Athena Neurosciences Inc Inhibitoren der leukozytenadhäsion
TW319763B (fr) 1995-02-01 1997-11-11 Epix Medical Inc
GB9502065D0 (en) 1995-02-02 1995-03-22 Nycomed Imaging As Contrast media
AU5752696A (en) 1995-05-18 1996-11-29 Regents Of The University Of Michigan, The Dna binding antibodies
US5891418A (en) * 1995-06-07 1999-04-06 Rhomed Incorporated Peptide-metal ion pharmaceutical constructs and applications
DE19539409C2 (de) 1995-10-11 1999-02-18 Diagnostikforschung Inst Kontrastmittel für die Nahinfrarot-Diagnostik
CA2232245C (fr) 1995-10-17 2011-06-07 Rohm Enzyme Finland Oy Cellulases, genes les codant et utilisation de ces cellulases
DK1325932T5 (da) 1997-04-07 2005-10-03 Genentech Inc Anti-VEGF antistoffer
IT1291623B1 (it) * 1997-04-18 1999-01-11 Bracco Spa Procedimento per la coniugazione di chelanti con molecole contenenti gruppi amminici
US6342598B1 (en) * 1998-11-26 2002-01-29 Bracco International B.V. Amphipatic polycarboxylic chelates and complexes with paramagnetic metals as MRI contrast agents
US6207858B1 (en) 1999-03-03 2001-03-27 Idec Pharmaceuticals Corporation Regioselective synthesis of DTPA derivatives
TWI290146B (en) * 1999-07-29 2007-11-21 Dyax Corp Binding moieties for fibrin
BR0013171A (pt) 1999-07-29 2002-05-28 Epix Medical Inc Agentes multimericos para formação de imagem de objetivação através de ligação multi-local
EP1218496A2 (fr) 1999-10-01 2002-07-03 Angstrom Pharmaceuticals, inc. SONDES DE DIAGNOSTIC ET AGENTS THERAPEUTIQUES DESTINES A CIBLER uPA ET uPAR
AU2119101A (en) 1999-10-22 2001-05-08 Insight Neuroimaging Systems, Llc Ligand chelated paramagnetic mri contrast agents
JP2003520255A (ja) * 2000-01-22 2003-07-02 エピックス メディカル， インコーポレイテッド 酵素的な切断によって生理活性化される造影剤プロドラッグを使用した磁気共鳴画像法
US6656448B1 (en) * 2000-02-15 2003-12-02 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
US6517814B2 (en) * 2001-01-09 2003-02-11 Bristol-Myers Squibb Pharma Company Macrocyclic chelants useful for metallopharmaceuticals
TWI240632B (en) * 2001-07-30 2005-10-01 Epix Medical Inc Purified peptides for peptide-based multimeric targeted contrast agents

Also Published As

Publication number Publication date
JP2005314438A (ja) 2005-11-10
IL160001A0 (en) 2004-06-20
US7238341B2 (en) 2007-07-03
CA2455638A1 (fr) 2003-02-13
PL368807A1 (en) 2005-04-04
YU9404A (sh) 2006-08-17
TWI284539B (en) 2007-08-01
AR036196A1 (es) 2004-08-18
KR20080100856A (ko) 2008-11-19
AU2002318931B2 (en) 2008-01-17
JP4298501B2 (ja) 2009-07-22
EP1420681A4 (fr) 2009-08-05
US20030180222A1 (en) 2003-09-25
CO5560528A2 (es) 2005-09-30
CN1599577A (zh) 2005-03-23
KR20040020074A (ko) 2004-03-06
US20050074411A1 (en) 2005-04-07
EA200400241A1 (ru) 2004-06-24
TWI240632B (en) 2005-10-01
UA84432C2 (ru) 2008-10-27
ZA200401606B (en) 2005-05-03
US6991775B2 (en) 2006-01-31
MXPA04000967A (es) 2005-02-17
NZ531338A (en) 2005-08-26
HUP0402029A2 (hu) 2005-01-28
US20030216320A1 (en) 2003-11-20
US20070185311A1 (en) 2007-08-09
US7927581B2 (en) 2011-04-19
CA2455638C (fr) 2013-01-22
US20060039861A1 (en) 2006-02-23
TW200512006A (en) 2005-04-01
JP2004536875A (ja) 2004-12-09
BR0211623A (pt) 2004-07-13
EA006239B1 (ru) 2005-10-27
ECSP044996A (es) 2004-06-28
WO2003011115A3 (fr) 2003-05-22
WO2003011115A2 (fr) 2003-02-13
NO20040402L (no) 2004-03-25
EP1420681B1 (fr) 2013-12-25
EP1420681A2 (fr) 2004-05-26
HUP0402029A3 (en) 2010-01-28

Similar Documents

Publication Publication Date Title
UA81226C2 (en) Peptide-based multimeric targeted contrast agents
Chen et al. MicroPET imaging of breast cancer αv-integrin expression with 64Cu-labeled dimeric RGD peptides
KR100932827B1 (ko) 펩티드계 화합물
CN103224495B (zh) 含有短氨基醇链的化合物和用于医学成像的金属络合物
AU2002318931A1 (en) Peptide-based multimeric targeted contrast agents
DE60206272T2 (de) Chelatorkonjugate mit verbesserten eigenschaften
WO2008017122A1 (fr) Agent de contraste dendrimère de polylysine
US6534038B2 (en) Ternary ligand complexes useful as radiopharmaceuticals
WO2009134382A2 (fr) Cyclopeptides contenant des mimétiques rgd servant de marqueurs d'imagerie pour des intégrines
JP6952320B2 (ja) 新規ｎｋ３受容体アゴニスト
KR20000070544A (ko) 중합체
KR20070029200A (ko) 펩티드계 화합물
WO2001052898A9 (fr) Procedes permettant d'incorporer des chelateurs de metaux a des sites de peptides a terminaison carboxyle
JP2001504801A (ja) 血栓サイトに局在化可能な放射性医薬組成物
AU2008201709A1 (en) Peptide-based Multimeric Targeted Contrast Agents